Bausch + Lomb Co. (NYSE:BLCO) Shares Sold by ExodusPoint Capital Management LP

ExodusPoint Capital Management LP cut its holdings in Bausch + Lomb Co. (NYSE:BLCO - Free Report) by 60.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 366,721 shares of the company's stock after selling 557,760 shares during the quarter. ExodusPoint Capital Management LP owned 0.10% of Bausch + Lomb worth $6,623,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Blue Trust Inc. increased its stake in Bausch + Lomb by 68.3% in the 4th quarter. Blue Trust Inc. now owns 2,474 shares of the company's stock valued at $48,000 after purchasing an additional 1,004 shares in the last quarter. FNY Investment Advisers LLC acquired a new position in shares of Bausch + Lomb during the 4th quarter worth $72,000. Commonwealth Equity Services LLC purchased a new stake in shares of Bausch + Lomb in the 4th quarter worth about $181,000. Orion Portfolio Solutions LLC acquired a new stake in Bausch + Lomb in the 4th quarter valued at about $225,000. Finally, Gordian Capital Singapore Pte Ltd purchased a new position in Bausch + Lomb during the 3rd quarter valued at about $289,000. Institutional investors and hedge funds own 11.07% of the company's stock.

Bausch + Lomb Trading Down 12.1 %

Shares of NYSE BLCO traded down $1.52 during trading on Thursday, hitting $11.01. 358,607 shares of the company traded hands, compared to its average volume of 622,606. The company has a quick ratio of 1.01, a current ratio of 1.60 and a debt-to-equity ratio of 0.72. The firm has a market capitalization of $3.89 billion, a P/E ratio of -12.05, a P/E/G ratio of 0.85 and a beta of 0.54. The company has a 50-day moving average price of $15.30 and a 200-day moving average price of $17.71. Bausch + Lomb Co. has a 1 year low of $10.46 and a 1 year high of $21.69.

Remove Ads

Bausch + Lomb (NYSE:BLCO - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $0.25 EPS for the quarter, topping the consensus estimate of $0.23 by $0.02. Bausch + Lomb had a positive return on equity of 3.35% and a negative net margin of 6.62%. The company had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the prior year, the firm posted $0.24 earnings per share. The firm's revenue was up 9.1% on a year-over-year basis. On average, equities analysts predict that Bausch + Lomb Co. will post 0.74 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on BLCO. Bank of America cut their price objective on Bausch + Lomb from $18.00 to $17.00 and set an "underperform" rating for the company in a research report on Thursday, February 20th. Royal Bank of Canada reduced their price objective on Bausch + Lomb from $18.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, April 4th. Stifel Nicolaus dropped their price objective on Bausch + Lomb from $17.00 to $15.00 and set a "hold" rating for the company in a research report on Thursday, April 3rd. Citigroup lowered shares of Bausch + Lomb from a "buy" rating to a "neutral" rating and reduced their target price for the company from $24.00 to $22.00 in a report on Wednesday, December 11th. Finally, HC Wainwright reissued a "buy" rating and issued a $23.00 price objective on shares of Bausch + Lomb in a research report on Tuesday, February 18th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company's stock. According to MarketBeat, Bausch + Lomb presently has a consensus rating of "Hold" and a consensus target price of $18.82.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.